92Bio revives a T cell engager it had transferred to Amgen

Ben Buelow, 92Bio CEO July 1, 2026 09:30 AM EDTUpdated 09:43 AM StartupsR&D A dis­card­ed Am­gen T cell en­gager comes back to life at its Cal­i­for­nia cre­ator, 92Bio Kyle LaHucik Biotech Correspondent A small Cal­i­for­nia start­up is re­viv­ing an ex­per­i­men­tal T cell en­gager that its sci­en­tists orig­i­nal­ly de­vel­oped but had hand­ed off to Am­gen years ago. Af­ter … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER